Member Info for MickTKipper

Fantastic update....AHEAD OF GUIDANCE............. http://www.investegate.co.uk/acacia-mining-plc--aca-/prn/4th-quarter-production-results/20150116070000P20DA/

Borrowed from across the road thanks go to Harry. Part of the Numis note today: "We revise our recommendations and target prices on the back of our new commodity price forecasts. Our ongoing caution on the mining sector appears well founded as price plunges continue unabated. 2015 looks set for another year of pain as a headwind of weak prices bite into company profits, despite some saving grace from lower oil and other input costs. As we highlighted in our last sector piece, downgrades, cost cuts, dividends and asset revaluations are likely to be atheme through this year as miners struggle to operate in a lower price environment. On a longer term view, there is value to be had by sticking to quality names and avoiding risk, perceived or otherwise. We continue to recommend a more defensive stance with Acacia, Fresnillo and Petra our picks. ● Growth, Quality & Management. We stick with our defensive criteria; we move Acacia to a pick, replacing a fully-valued Randgold, a quality company which still has to prove its stripes, but has potential for high reward. The share price has been strong and looks overbought at these levels but we see plenty of room to deliver. Alongside Fresnillo and Petra, these all have superior growth profiles to counteract flat to falling commodity prices, high quality assets to weather any downturn and strong management to deliver on business plans. We have no copper pick given price headwinds, limited growth and short term challenges. Berkeley and Highfield are our favoured juniors, with quality projects in excellent jurisdictions and recovering commodities. Many other covered stocks have attractive investment opportunities but in subdued commodities which are struggling to see a positive price response.

Breakout confirmed. From tuesday....... just found this on advfn..... Motley Fool today > With profit having fallen over the last couple of years and its share price being 52% lower than three years ago, it's been a tough period for Fresnillo (LSE: FRES). Still, its shares continue to trade on a very rich multiple of 31 and, looking ahead to its growth forecasts, they seem to be worth it. That's because Fresnillo is expected to increase its bottom line by 51% in the current year, followed by 34% next year. Part of the reason for this is its ultra-low cost base that, as the largest silver producer in the world, allows it to maintain relatively high levels of production while many of its rivals struggle to turn a profit. As such, its bottom line looks set to benefit and, with a PEG ratio of just 0.6, investors in the company could benefit from a higher share price moving forward, too.

15 Jan 2015 Laird PLC LRD Liberum Capital Buy 0.00 309.20 350.00 350.00 Reiterates. SP TARGET 350p.

<b>Investec says Supergroup's valuation "undemanding" given growth potential</b> 14 January 2015 10:16 A return to strong positive like-for-like (LFL) sales growth in the third quarter at Supergroup "should be welcomed" by the market, according to Investec which lifted its target price for the fashion retailer on Wednesday. The broker, which lifted its earnings estimates for the firm, upped its target for the shares from 1,000p to 1,030p and reiterated its 'buy' recommendation. Following on from a 4.2% drop in LFL sales in the second quarter, Supergroup said LFLs improved by an impressive 12.5% in the 11 weeks to 10 January. "Whist up against a soft comparable, the strength of growth is likely to surprise, as well as the fact that there has been a material acceleration in estimated two-year LFL [run rate] to at least double digit, from Q2's +3.3%," said Investec analyst Kate Calvert. She said that the retailer's performance was "consistent" across mens and womenswear as well as the UK and Europe. Investec has raised its profit before tax forecast for the fiscal year ending 30 April by 3.4% to £62.5m. This remains in line with the company's guidance of £60m-65m, with Calvert saying that strong sales will not directly benefit profits as they will be partially offset by foreign exchange movements, bad debt with a big wholesale customer, costs and tactical issues. "Valuation looks undemanding for a business capable of delivering consistent double-digit growth given the longer term opportunities, both within the UK and Internationally," the analyst said. "More consistent delivery should drive a re-rating over time." The stock was up nearly 10% at 891.5p by 10:57. Related Companies: SGP

23rd October 2014 Interim Management Statement.... Outlook Although the longer term outlook for London property markets remains positive, the market is expected to continue to be constrained for some time due to political and economic uncertainty within the UK and Europe, tighter mortgage lending markets and mismatches between the price expectations of buyers and sellers. These external headwinds have exacerbated the rate of slowdown in sales transactions we noted at the time of our H1 results. Market volumes in Q3 have been more in line with the first half of 2013 and we now believe that market volumes in H2 2014 overall will be significantly below levels during the same period last year. Consequently, we expect full year 2014 adjusted EBITDA to be below the prior year figure of £49.6m.

PIC PACE 13 Jan 15 JP Morgan Cazenove Overweight 358.90 441.00 444.00 Reiterates 441p SP TARGET

FRES Fresnillo from John Burford iii 12/01/2015 Update - Fresnillo I featured this very interesting share on 8 December with this chart updated on 29 December: http://content.screencast.com/users/thomaser/folders/Default/media/c77df143-f05e-425d-85f6-0dc3f8ca1479/fres%203.jpg" I show a lovely textbook five down to sub-700p and then a large wedge (see text, pp 33-38, 71-80, 152) in formation. This had all the appearance of a basing operation. I reckoned that if the market could break above the upper green line that would set the seal for a vigorous rally. Another factor in support of my bullish forecast was the extremely bearish market sentiment towards gold/silver. Most pundits expect the PMs to decline with a commonly-held target for gold to sub-$1,000. I had the exact opposite view. Now, just last week, the market broke up with gold out of the wedge on strength: http://content.screencast.com/users/thomaser/folders/Default/media/29705e19-c16f-4dd5-9e54-a7deb7e606b1/fres%204.jpg" This now sets up my probable Elliott wave roadmap. If my labels are correct, we are in a third wave up - and these are generally long and strong. My first target is just above at the 850 area (the Fibonacci 50% level), but much higher targets beckon. <b>Another charting target based on the wedge thickness at the left hand edge is the 900 area. As I wrote in December, this share holds great potential for appreciation over the next few months.</b>

FRES Fresnillo.On the verge of a breakout into a bullish resistance wall which could see the SP hit 980p pretty quickly, EMA golden x on chart aswel. Depends on wether silver and gold to a lesser extent can maintain there present levels and not fall through support. https://pbs.twimg.com/media/B7KlcjECIAEdXSY.jpg"

Vectura to present at JP Morgan Conference RNS RNS Number : 5910B Vectura Group plc 09 January 2015 &#65279; Vectura Group plc Vectura to present at the 33rd Annual J.P. Morgan Healthcare Conference, San Francisco Chippenham, UK - 9 January 2015: Vectura Group plc ("Vectura"; LSE: VEC) announces today that it is scheduled to present at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, 14 January 2014, at 4:30pm PST (12.30am 15 January GMT). The conference runs from 11-15 January 2015, at the Westin St. Francis Hotel in San Francisco, CA. The presentation will be webcast live and can be reached from Vectura's website at http://www.vectura.com/investors/reports-presentations/2015.aspx. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software. A PDF of the presentation will also be available on Vectura's website at the same time. -Ends- Enquiries Vectura Group plc +44 (0)1249 667700 Karl Keegan, Chief Corporate Development Officer Fleur Wood, Corporate Investor Relations FTI Consulting +44 (0)20 3727 1000 Ben Atwell / John Dineen / Ulla Lundhus

More here about this being a "multi-million dollar" deal: Http://www.businessweekly.co.uk/biomedtech-/18009-vectura-clinches-multi-million-dollar-janssen-deal Extract: "Tuesday, 06 January 2015 09:08 Tony Quested Vectura clinches multi-million dollar Janssen deal . Vectura in Cambridge UK has secured a landmark deal with US heavyweight Janssen Biotech Inc to develop inhaler technology to treat asthma and COPD (chronic obstructive pulmonary disease). While no financial deals were disclosed to the markets, Business Weekly understands the payback stacks up to several million dollars. The deal comprises handsome upfront and development milestones and a tiered royalty on net sales. etc"

From Peel Hunt wed - nice 248p target price. Janssen's prior acquisition of Respivert is certainly an intriguing portent.... "Vectura (Buy TP 248p) Janssen deal. Vectura announced a deal with Janssen Biotech (part of J&J and developer of approved drugs such as Zytiga) for the exclusive development of Janssen's novel anti-inflammatory therapies in development for the treatment of asthma/COPD. The collaboration will initially focus on the development of a Phase 2 candidate, with the potential to include additional clinical-stage candidates. Janssen will lead the clinical development of the assets, with Vectura providing its expertise and technologies (devices, formulation) in dry powder inhalers (DPI). This deal is in line with the strategy outlined at the Business Review Day last March, which unveiled Vectura's Gyrohaler-related devices platform, which includes several different device options, as an approved multi-dose DPI platform available for licensing. Detailed deal terms are not disclosed, but we would imagine a typical structure of modest 7 figure upfronts and milestones together with full FTE funding of Vectura resources (people) and mid single digit royalties on eventual sales. Such a structure implies no rise in Vectura's own R&D investment, though will utilise some of the bandwidth of its employee base, in return for near-term milestones and development services payments and a share in the upside should the products get to market. The precise products are not disclosed, but note that Janssen acquired the UK companyRespivert a few years ago, which has a promising portfolio of anti-inflammatory compounds in development. This deal is a positive step forward, adding a further large pharma partner and is exactly in line with Vectura's stated strategy and is a validation of its status as a partner of choice in targeting airways diseases. We make no changes to our valuation at the moment pending more information on this programme in the future."

VEC Vectura- Pharma/Bio co. Long,secured deals over last few days with some big US companys Risky but broker backing is very strong. https://pbs.twimg.com/media/B61OlBPCQAAESIB.jpg Date Broker Rec. Price Old target price New target price Notes 08 Jan 15 Oriel Securities Buy 150.50 207.00 207.00 Reiterates 08 Jan 15 Investec Buy 150.50 148.00 163.00 Upgrades 08 Jan 15 N+1 Singer Hold 150.50 147.00 156.00 Retains 07 Jan 15 Canaccord Genuity Buy 150.50 192.00 192.00 Reiterates 06 Jan 15 finnCap Buy 150.50 202.00 202.00 Reiterates 05 Jan 15 JP Morgan Cazenove Overweight 150.50 230.00 230.00 Reiterates

JE. Just Eat. Online marketplace for restaurant delivery. Should have had good trading over 2 wc XMAS Period. Citygroup have 495p SP Target. Jefferies SP Target 450p. https://pbs.twimg.com/media/B6qvzD1CYAA2YlX.jpg

Just Eat broker views Date Broker Recommendation Price Old target price New target price Notes 03 Dec Citigroup Buy 330.75 - 495.00 Initiates/Starts 03 Nov Jefferies International Buy 330.75 450.00 450.00 Reiterates 03 Nov JP Morgan Cazenove Overweight 330.75 - - Reiterates

GRG Greggs On the verge of a breakout from the short term range and a new high. Results on the 13th next week. https://pbs.twimg.com/media/B6veogGCQAE7eRE.jpg

Date Broker Recommendation Price Old target price New target price Notes 07 Jan Liberum Capital Buy 112.88 - 160.00 Reiterates 07 Jan Cantor Fitzgerald Buy 112.88 125.00 125.00 Reiterates

BRIEF – Topps Tiles posts 6.0 pct rise in Q1 like – for – like sales 07 Jan 2015 - 07:21 Jan 7 (Reuters) – Topps Tiles Plc Like-For-Like revenues across first 13 weeks of current financial year increased by 6.0% Source text for Eikon: ... Further company coverage: TPT.L (Editing by Neil Maidment) ((neil.maidment@thomsonreuters.com;) Keywords: TOPPSTILES/BRIEF

Very good results on the back of outstanding results last year.... Matthew Williams, Chief Executive Officer, said: "I am delighted to report an encouraging start to our financial year with like-for-like sales growth of 6.0% in the first quarter. This is particularly pleasing as it builds on our strong sales growth in the corresponding period in the prior year. We are confident that our plan for 2015 will see us further extend the appeal of the Topps brand and move closer to our strategic goal of taking a one third share of the domestic tile market."

05 Jan 2015 Ashtead Group PLC AHT Panmure Gordon Buy 1,183.50 1,165.00 - 1,457.00 Reiterate SP TARGET 1457p